Sonntag, 17. Januar 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 

JOURNAL ONKOLOGIE – STUDIE

Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies

Rekrutierend

NCT-Nummer:
NCT04641871

Studienbeginn:
Oktober 2020

Letztes Update:
31.12.2020

Wirkstoff:
Sym021, Sym022, Sym023

Indikation (Clinical Trials):
Neoplasms, Neoplasm Metastasis

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 1

Sponsor:
Symphogen A/S

Collaborator:
-

Studienleiter

Nehal Lakhani, MD
Principal Investigator
START Midwest

Kontakt

Studienlocations (3 von 28)

Interdisziplinäres Brustzentrum der Charité im Charité Comprehensive Cancer Center
Virchowweg 23
10117 Berlin
(Berlin)
DeutschlandNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Sebastian Ochsenreiter, MD
» Ansprechpartner anzeigen
Universitaetsklinikum Carl Gustav Carus TU Dresden
01307 Dresden
(Sachsen)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Martin Wermke, MD
Phone: +49 (0)351 458-7566
E-Mail: martin.wermke@uniklinikum-dresden.de
» Ansprechpartner anzeigen
Universitaetsklinikum Hamburg-Eppendorf
20246 Hamburg
(Hamburg)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Gunhild von Amsberg, MD
Phone: +4940741050662
E-Mail: g.von-amsberg@uke.de
» Ansprechpartner anzeigen
University of Chicago
60637-1470 Chicago
United StatesNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Chih-Yi "Andy" Liao, MD
Phone: 773-702-6241
E-Mail: andyliao@medicine.bsd.uchicago.edu
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

The study will evaluate safety and efficacy in participant with small cell lung cancer,

urothelial cancer and bladder cancer who have developed resistance to prior anti-PD1 or

anti-PD-L1 therapy and in patient with cholangiocarcinoma who have received at least 1 line

of standard of care therapy and have progressed on it.

Per 22nd of December 2020 recruitment for small cell lung cancer, urothelial cancer and

bladder cancer has temporarily stopped due to strategy considerations. Recruitment for

cholangiocarcinoma is still open.

Ein-/Ausschlusskriterien

Inclusion Criteria:

Patients must meet all the following criteria to be eligible for participation in the

study:

- Male or female patients, ≥18 years.

- Patients with documented (histologically or cytologically proven) unresectable,

locally advanced, or metastatic malignancies:

1. Urothelial cancer (UC)

2. Small cell lung cancer (SCLC)

3. Endometrial cancer (EC) of any histological subtype

4. Cholangiocarcinoma (CCA): unresectable or metastatic adenocarcinoma of the intra-

and/or extra-hepatic bile ducts

- Patients with UC, SCLC, and EC must have received prior anti-PD-(L)1 therapy with a

best response of CR/PR or durable SD

- Patients with measurable disease according to RECIST v1.1

- Patients with an ECOG PS of 0 or 1, and anticipated life expectancy of ≥3 months

- Patients must have adequate organ function as indicated by laboratory values

- Adequate contraception required as appropriate

Exclusion Criteria:

- Has central nervous system (CNS) malignancies

- Patients with significant cardiovascular disease

- Patients with

1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism,

within 4 weeks prior to the first study drug dose

2. Active uncontrolled bleeding or a known bleeding diathesis

- Patients with a significant pulmonary disease or condition

- Patients with a current or recent (within 6 months) significant gastrointestinal

disease or condition

- Patients with a significant ocular disease or condition

- Patients with an active, known or suspected autoimmune disease

- Patients with any other serious/active/uncontrolled infection

- Prior therapy with anti-LAG-3 or anti-TIM-3 or combinations of these 2 antibodies with

anti-PD-(L)1 antibody or with any other systemic or localized therapy

- Patients with a history of significant toxicities associated with previous

administration of immune checkpoint inhibitors that necessitated permanent

discontinuation of that therapy

- Patients with a known or suspected hypersensitivity to any of the excipients of

formulated study drug

- Patients with unresolved >Grade 1 toxicity associated with any prior antineoplastic

therapy

Studien-Rationale

Primary outcome:

1. To evaluate the preliminary efficacy of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) in each tumor type under study by assessing ORRs per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Time Frame - Until disease progression or end of study, whichever comes first, assessed up to 24 months):
Objective Response Rate (ORR) per Investigator assessment of antitumor activity (based on radiological evidence per RECIST v1.1)

2. To evaluate the incidence, severity, and relationship of (S)AEs collected from administration of the first dose of study drug until 30 days after the last dose of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) (Time Frame - Through study completion up to 30 days after last dose of the two combinations):
Calculation of AE incidence will be based on the number of patients per AE category; AEs in total and sorted by frequency, AEs by relationship, SAEs in total and by relationship, Immune mediated AEs, Fatal AEs

3. To evaluate the AEs leading to dose interruption, dose delays, and permanent treatment stop of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) (Time Frame - Through study completion up to a maximum of 12 months):
Calculation of AE incidence will be based on the number of patients per AE category ; AEs leading to dose interruption, dose delays, and permanent treatment stop

Secondary outcome:

1. Peak Plasma Concentration (Cmax) of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) (Time Frame - First dose of study drug):
Peak Plasma Concentration (Cmax) for first dose of each drug in each combination. Will be derived from observed data

2. To confirm the RP2D of each combination (Time Frame - 36 month):
Confirmation of the RP2D, based on the dose-response relationship (in case more than one dose level is implemented), overall tolerability and safety profile, and the PK and pharmacodynamic data

3. Evaluation of duration of response. (Time Frame - Until disease progression or end of study, whichever comes first, assessed up to 24 months):
Will be calculated from the day the initial response is observed to the day progression of disease is observed

4. To evaluate the immunogenicity of each drug in the combinations (Time Frame - From screening up to 30 month):
Occurrence of ADA measured in serum at selected timepoints during the study

5. Area under the plasma concentration versus time curve (AUC) of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) (Time Frame - First study drug dose):
Area under the plasma concentration versus time curve (AUC) for first dose of each drug in each combination. Will be estimated using non-compartmental methods and actual time points

6. Time to reach maximum concentration (Tmax) of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) (Time Frame - First study drug dose):
Time to reach maximum concentration (Tmax) for first dose of each drug in each combination. Will be derived from observed data.

7. Trough concentration (Ctrough) of the 2 combinations (Sym021+Sym022 and Sym021+Sym023) (Time Frame - First dose of study drug):
Trough concentration (Ctrough) for first dose of each drug in each combination. Will be derived from observed data.

8. Evaluation of Progression-Free Survival (PFS) (the PFS rate at 6 months will additionally be evaluated in patients with SCLC) (Time Frame - From first study drug dose until disease progression or end of study, whichever comes first, assessed up to 24 months):
Will be calculated as from the first study drug dose to the day progression of disease is confirmed radiological or date of death.

9. Evaluation of Disease Control Rate (DCR), defined as CR, PR, or stable disease (SD) ≥6 months (Time Frame - Until disease progression or end of study, whichever comes first, assessed up to 6 months):
Will be calculated according to standard response criteria

10. Evaluation of Objective Response Rate (ORR) per Investigator assessment (based on Immunotherapeutics Response Evaluation Criteria in Solid Tumors [iRECIST]) (Time Frame - Until disease progression or end of study, whichever comes first, assessed up to 24 months):
Will be based on Investigators assessment on Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST)

11. Evaluation Overall Survival (OS) (Time Frame - From first dose of study drug until death or latest survival follow-up assessed up to 30 month):
Overall survival will be derived from start of treatment until death or latest survival follow-up.

Studien-Arme

  • Experimental: Sym021+Sym022 [ARM A]
    Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
  • Experimental: Sym021+Sym023 [ARM B]
    Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.

Geprüfte Regime

  • Sym021 (Anti-PD-1):
    IV infusion over 30 minutes on day 1 and 15 of each cycle.
  • Sym022 (Anti-LAG-3):
    IV infusion over 30 minutes on day 1 and 15 of each cycle.
  • Sym023 (Anti-TIM-3):
    IV infusion over 30 minutes on day 1 and 15 of each cycle.

Quelle: ClinicalTrials.gov


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie